Vaginal bleeding and a giant ovarian cyst in an infant with 21-hydroxylase deficiency

J Pediatr Endocrinol Metab. 2018 Jan 26;31(2):229-233. doi: 10.1515/jpem-2017-0235.

Abstract

Background: Increased adrenal androgen hormones in congenital adrenal hyperplasia (CAH) can rarely cause giant ovarian cysts in the neonatal period. Although the exact mechanism of the development of ovarian cysts is unknown, it is thought that increased androgen levels stimulate folicle development by increasing follicle stimulating hormone (FSH) levels.

Case presentation: A 16-day-old newborn with ambiguous genitalia was presented to our clinic. Laboratory test results were as follows: sodium: 126 mEq/L, potassium: 5.4 mEq/L, renin: 132 pg/mL, adrenocorticotropic hormone (ACTH): 207 pg/mL, cortisole: 7.8 μg/dL, basal 17OH progesterone: 21 ng/mL, androstenedione: 5.1 ng/mL, testosterone: 1188 ng/dL and dehydroepiandrosterone sulfate (DHEAS)>1500 μg/dL. Karyotype analysis resulted in 46,XX. A homozygous mutation of R356W was detected in the CYP21A2 gene. The classical severe form of salt wasting 21 hydroxylase deficiency was diagnosed and treatment was started with hydrocortisone and fludrocortisone. Good metabolic control was ensured by monthly visits but the baby presented with vaginal bleeding as soiling at 4 months. The cystic lesion which extended to the epigastric area from the pelvis in the midline abdomen, had a size of 90×80×60 mm and medially, thin ovarian parenchyma was detected in ultrasonography.

Conclusions: The findings in our patient suggest that a decline in adrenal androgens after glucocorticoid treatment resulted in an increase in gonadotropin levels and the giant cyst is developed by activation of gonadotropin cascade and increased gonadotropin receptors, instead of androgens.

Keywords: 21-hydroxylase deficiency; congenital adrenal hyperplasia; giant ovarian cyst; gonadotropin cascade; vaginal bleeding.

Publication types

  • Case Reports

MeSH terms

  • 46, XX Disorders of Sex Development / drug therapy*
  • 46, XX Disorders of Sex Development / genetics
  • Adrenal Hyperplasia, Congenital / drug therapy*
  • Adrenal Hyperplasia, Congenital / genetics
  • Amino Acid Substitution
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Drug Therapy, Combination / adverse effects
  • Female
  • Fludrocortisone / adverse effects
  • Fludrocortisone / therapeutic use
  • Gonadotropins / adverse effects*
  • Gonadotropins / therapeutic use
  • Homozygote
  • Humans
  • Hydrocortisone / adverse effects
  • Hydrocortisone / therapeutic use
  • Infant, Newborn
  • Mutation
  • Ovarian Cysts / chemically induced*
  • Ovarian Cysts / pathology
  • Ovarian Cysts / physiopathology
  • Ovarian Cysts / surgery
  • Ovary / drug effects*
  • Ovary / pathology
  • Ovary / surgery
  • Steroid 21-Hydroxylase / genetics
  • Treatment Outcome
  • Tumor Burden
  • Uterine Hemorrhage / etiology*
  • Uterine Hemorrhage / prevention & control

Substances

  • Anti-Inflammatory Agents
  • Gonadotropins
  • CYP21A2 protein, human
  • Steroid 21-Hydroxylase
  • Fludrocortisone
  • Hydrocortisone

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency